Tara Landry

Tara Landry

Auto-generated profile, based on publicly available information

Tara Landry

Bibliothèque de la Santé, Universite de Montreal, Montreal, Quebec, Canada

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2016 in Surgery
Verified
Journal Article
Closed access
TCTanya Castelino
Tanya Castelino
JFJulio F. Fiore
Julio F. Fiore
PNPetru Niculiseanu
Petru Niculiseanu
TLTara Landry
Tara Landry
BABerson Augustin
Berson Augustin
LFLiane S. Feldman
Liane S. Feldman

1 March 2016 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
JFJulio F. Fiore
Julio F. Fiore
JBJimmy Bejjani
Jimmy Bejjani
KCKate Conrad
Kate Conrad
PNPetru Niculiseanu
Petru Niculiseanu
TLTara Landry
Tara Landry
LFLiane S. Feldman
Liane S. Feldman

1 April 2014 in Annals of Surgery
Verified
Journal Article
Closed access
LLLawrence Lee
Lawrence Lee
CLChao Li
Chao Li
TLTara Landry
Tara Landry
ELEric Latimer
Eric Latimer
FCFranco Carli
Franco Carli
LFLiane S. Feldman
Liane S. Feldman
To perform a systematic review of economic evaluations of enhanced recovery pathways (ERP) for colorectal surgery. Although there is extensive literature investigating the clinical effectiveness of ERP, little is known regarding its cost-effectiveness. A systematic literature search identified all relevant articles published between 1997 and 2012 that performed an economic evaluation of ERP for colorectal surgery. Studies were included only if their ERP included all 5 of the key components (patient information, preservation of GI function, minimization of organ dysfunction, active pain control, and promotion of patient autonomy). Quality assessment was performed using the Consensus on Health Economic Criteria instrument (scored 0-19; high quality ≥ 12). Incremental cost-effectiveness ratios were calculated if sufficient data were provided, using difference in length of stay and overall complication rates as effectiveness measures. Of a total of 263 unique records identified (253 from databases and 10 from other sources), 10 studies met our inclusion criteria and were included for full qualitative synthesis. Overall quality was poor (mean quality 7.8). Eight reported lower costs for ERP. The majority (8 of 10) of studies were performed from an institutional perspective and therefore did not include costs related to changes in productivity and other indirect costs (eg, caregiver burden). Five studies provided enough information to calculate ICERs, of which ERP was dominant (less costly and more effective) in all cases for reduction in length of stay and was dominant or potentially cost-effective in 4 and questionable (no difference in costs nor effectiveness) in 1 for reduction in overall complications. The quality of the current evidence is limited but tends to support the cost-effectiveness of ERP. There is need for well-designed trials to determine the cost-effectiveness of ERP from both the institutional and societal perspectives.

29 November 2019 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
AKAmanpreet Kaur
Amanpreet Kaur
SMSharon T Mackin
Sharon T Mackin
KSKenny Schlosser
Kenny Schlosser
FWFui Lin Wong
Fui Lin Wong
MEMalik Elharram
Malik Elharram
LPLouise Pilote
Louise Pilote
The aim of this systematic review was to assess dysregulated miRNA biomarkers in coronary artery disease (CAD). Dysregulated microRNA (miRNAs) have been shown to be linked to cardiovascular pathologies including CAD and may have utility as diagnostic and prognostic biomarkers. We compared miRNAs identified in acute coronary syndrome (ACS) compared with stable CAD and control populations. We conducted a systematic search of controlled vocabulary and free text terms related to ACS, stable CAD and miRNA in Biosis Previews (OvidSP), The Cochrane Library (Wiley), Embase (OvidSP), Global Health (OvidSP), Medline (PubMed and OvidSP), Web of Science (Clarivate Analytics), and ClinicalTrials.gov which yielded 7370 articles. Of these, 140 original articles were appropriate for data extraction. The most frequently reported miRNAs in any CAD (miR-1, miR-133a, miR-208a/b, and miR-499) are expressed abundantly in the heart and play crucial roles in cardiac physiology. In studies comparing ACS cases with stable CAD patients, miR-21, miR-208a/b, miR-133a/b, miR-30 family, miR-19, and miR-20 were most frequently reported to be dysregulated in ACS. While a number of miRNAs feature consistently across studies in their expression in both ACS and stable CAD, when compared with controls, certain miRNAs were reported as biomarkers specifically in ACS (miR-499, miR-1, miR-133a/b, and miR-208a/b) and stable CAD (miR-215, miR-487a, and miR-502). Thus, miR-21, miR-133, and miR-499 appear to have the most potential as biomarkers to differentiate the diagnosis of ACS from stable CAD, especially miR-499 which showed a correlation between the level of their concentration gradient and myocardial damage. Although these miRNAs are potential diagnostic biomarkers, these findings should be interpreted with caution as the majority of studies conducted predefined candidate-driven assessments of a limited number of miRNAs (PROSPERO registration: CRD42017079744).

1 December 2016 in Hypertension
Verified
Journal Article
Closed access
PDF file
SGSophie Grand’mAison
Sophie Grand’mAison
LPLouise Pilote
Louise Pilote
MOMarisa Okano
Marisa Okano
TLTara Landry
Tara Landry
NDNatalie Dayan
Natalie Dayan
Women with prior hypertensive disorders of pregnancy (HDP) are at twice the risk of cardiovascular disease compared with women with prior normotensive pregnancy, possibly because of sustained vascular dysfunction after delivery. The aim of this systematic review and meta-analysis is to summarize evidence of vascular dysfunction at least 3 months after HDP. Articles in all languages were retrieved from principal databases. Studies included were observational, with HDP as the main exposure and measurements of vascular dysfunction via imaging modalities or serum biomarkers as the main outcome, assessed at least 3 months postpartum. We pooled results of modalities reported in >3 studies using a random effects model. Of 6109 potentially relevant studies, 72 were included that evaluated 10 imaging modalities and 11 serum biomarkers in 8702 women. There was evidence of vascular dysfunction in women post HDP compared with women with prior normal pregnancy when measured by carotid-femoral pulse wave velocity (0.64 m/s [0.17–1.11]), carotid intima–media thickness (0.025 mm [0.004–0.045]), and augmentation index (5.48% [1.58–9.37]), as well as mean levels of soluble fms-like tyrosine kinase (6.12 pg/mL [1.91–10.33]). Between-groups differences in measures of vascular dysfunction were more pronounced when assessments were performed in younger women (<40 years) or closer to the index pregnancy for almost all modalities. In conclusion, pooled data from studies evaluating vascular imaging suggest that some vascular dysfunction persists after HDP as compared with women with prior normal pregnancy.

1 November 2019 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
JFJulio F. Fiore
Julio F. Fiore
GOGhadeer Olleik
Ghadeer Olleik
CECharbel El-Kefraoui
Charbel El-Kefraoui
BVBernardo Verdolin
Bernardo Verdolin
AKAraz Kouyoumdjian
Araz Kouyoumdjian
LFLiane S. Feldman
Liane S. Feldman